Evidence map›Paper›PMID 33690147›Full record

ArticleJournal of medical Internet research2021

Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study.

Felix Muehlensiepen, Johannes Knitza, Wenke Marquardt, Jennifer Engler, Axel Hueber, Martin Welcker

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Digital Approaches for Myositis.Current rheumatology reports · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Felix MuehlensiepenKV Consult- und Managementgesellschaft mbH, Potsdam, Germany.ORCID 0000-0001-8571-7286
Johannes KnitzaDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen- Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-9695-0657
Wenke MarquardtKV Consult- und Managementgesellschaft mbH, Potsdam, Germany.ORCID 0000-0003-1130-7748
Jennifer EnglerInstitut für Allgemeinmedizin, Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.ORCID 0000-0002-6030-1513
Axel HueberSektion Rheumatologie, Sozialstiftung Bamberg, Bamberg, Germany.ORCID 0000-0001-6454-1234
Martin WelckerMedizinisches Versorgungszentrum für Rheumatologie Dr M Welcker GmbH, Planegg, Germany.ORCID 0000-0002-1856-3085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe worldwide burden of musculoskeletal diseases is increasing. The number of newly registered rheumatologists has stagnated. Primary care, which takes up a key role in early detection of rheumatic disease, is working at full capacity. COVID-19 and its containment impede rheumatological treatment. Telemedicine in rheumatology (telerheumatology) could support rheumatologists and general practitioners.

objectiveThe goal of this study was to investigate acceptance and preferences related to the use of telerheumatology care among German rheumatologists and general practitioners.

methodsA nationwide, cross-sectional, self-completed, paper-based survey on telerheumatology care was conducted among outpatient rheumatologists and general practitioners during the pre-COVID-19 period.

resultsA total of 73.3% (349/476) of survey participants rated their knowledge of telemedicine as unsatisfactory, poor, or very poor. The majority of survey participants (358/480, 74.6%) answered that they do not currently use telemedicine, although 62.3% (291/467) would like to. Barriers to the implementation of telemedicine include the purchase of technology equipment (182/292, 62.3%), administration (181/292, 62.0%), and poor reimbursement (156/292, 53.4%). A total of 69.6% (117/168) of the surveyed physicians reckoned that telemedicine could be used in rheumatology. Surveyed physicians would prefer to use telemedicine to communicate directly with other physicians (370/455, 81.3%) than to communicate with patients (213/455, 46.8%). Among treatment phases, 64.4% (291/452) of participants would choose to use telemedicine during follow-up. Half of the participants would choose telecounseling as a specific approach to improve rheumatology care (91/170, 53.5%).

conclusionsBefore COVID-19 appeared, our results indicated generally low use but high acceptance of the implementation of telerheumatology among physicians. Participants indicated that the lack of a structural framework was a barrier to the effective implementation of telerheumatology. Training courses should be introduced to address the limited knowledge on the part of physicians in the use of telemedicine. More research into telerheumatology is required. This includes large-scale randomized controlled trials, economic analyses, and the exploration of user preferences.

Indexed as

Attitude of Health PersonnelCOVID-19Cross-Sectional StudiesFemaleGeneral PractitionersGermanyHumansMiddle AgedPandemicsRheumatologistsRheumatologySARS-CoV-2Surveys and QuestionnairesTelemedicineCOVID-19eHealthhealth services researchmHealthprimary carerheumatologytelemedicine

Identifiers

PMID33690147
PMCPMC8042540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.